Home > Insider Trading > Filing (0001209191-18-021551)

Filing Details

Accession Number:: 0001209191-18-021551
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-03-23 18:33:11
Reporting Period:: 2018-03-21

Accepted Time:: 2018-03-23 18:33:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1621227	Adaptimmune Therapeutics Plc	ADAP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1237289	D Scott Sandell	1954 Greenspring Drive Suite 600 Timonium MD 21093		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares With A Nominal Value Of 0.001 Gbp Per Share	Acquisiton	2018-03-21	104,844	$1.81	72,243,844	No	4	P	Indirect	See Note 3
Ordinary Shares With A Nominal Value Of 0.001 Gbp Per Share	Acquisiton	2018-03-22	869,574	$1.90	73,113,418	No	4	P	Indirect	See Note 3
Ordinary Shares With A Nominal Value Of 0.001 Gbp Per Share	Acquisiton	2018-03-23	294,090	$1.95	73,407,508	No	4	P	Indirect	See Note 3

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Note 3
No	4	P	Indirect	See Note 3
No	4	P	Indirect	See Note 3

Footnotes

The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
The price reported in Column 4 of $1.8105 per ordinary share is a weighted average price derived from the weighted average price of $10.8628 per ADS, divided by six. These ADSs were purchased in multiple transactions at prices ranging from $10.29 to $11.15 per ADS, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
The price reported in Column 4 of $1.904 per ordinary share is a weighted average price derived from the weighted average price of $11.4241 per ADS, divided by six. These ADSs were purchased in multiple transactions at prices ranging from $10.93 to $11.84 per ADS, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs purchased at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 of $1.9462 per ordinary share is a weighted average price derived from the weighted average price of $11.6773 per ADS, divided by six. These ADSs were purchased in multiple transactions at prices ranging from $11.41 to $12 per ADS, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs purchased at each separate price within the range set forth in this footnote (5) to this Form 4.